Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

BACKGROUND: Dabrafenib and trametinib combination therapy is approved for the treatment of patients with BRAF V600E positive tumors including melanoma and lung cancer. The effect of BRAF and MEK inhibitors on the immune system is not fully understood although a number of case reports indicate autoim...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimou, Anastasios, Barron, Gregory, Merrick, Daniel T., Kolfenbach, Jason, Doebele, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057580/
https://www.ncbi.nlm.nih.gov/pubmed/32131760
http://dx.doi.org/10.1186/s12885-020-6661-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057580/
https://www.ncbi.nlm.nih.gov/pubmed/32131760
http://dx.doi.org/10.1186/s12885-020-6661-6

Ejemplares similares